Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab Monotherapy in Stage 3B AL Amyloidosis
NCT04131309Phase 2Completed
- Start
- Sep 2019
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label trial of daratumumab in light-chain amyloidosis. Primary endpoint: Overall Survival at 6 months. Started Sep 2019; status: completed.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT04131309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04131309.